Brooks Laboratories Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2026 • Manufacturing: 96.7% • Trading: 3.3%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Operating margins have improved to 8.2% from -41.5%
- Company comfortably covers its interest (30.4x coverage)
CONS
- Company has a low return on capital employed of -4.4%
- Company has a low return on equity of -6.0% over last 3 years
- Promoter holding has decreased over last 2 years: -11.0pp
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -0.43x)
- Contingent liabilities are large at 100.2% of net worth
- Effective tax rate is unusually low at 0.0% - earnings may be flattered
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1933.00 | 38.34 | 463791.45 | 0.83 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9232.00 | 83.79 | 245080.59 | 0.33 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 5004.40 | 87.28 | 190351.29 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1151.20 | 25.44 | 114832.64 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1413.15 | 33.87 | 114162.52 | 0.92 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1863.00 | 92.06 | 100660.17 | 0.11 | 3620.70 | 2139.42 | 20263.10 | 1191.00 | 18.20 | 31.50 |
| LUPIN | 2152.60 | 17.80 | 98431.05 | 0.84 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2380.00 | 48.13 | 98304.73 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| DRREDDY | 1161.00 | 30.07 | 96906.34 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1656.30 | 25.67 | 95299.84 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| GLENMARK | 2451.70 | 38.49 | 69193.02 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| BROOKS | 66.69 | 14.87 | 196.45 | 0.00 | -1.79 | -101.86 | 22.96 | -9.99 | 21.72 | -5.85 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16 | 24 | 22 | 18 | 18 | 21 | 21 | 23 | 26 | 23 | 17 | 20 | 23 | |
| 16 | 23 | 21 | 17 | 18 | 19 | 19 | 22 | 22 | 21 | 16 | 20 | 22 | |
| Operating Profit | 0 | 2 | 1 | 0 | 0 | 2 | 2 | 2 | 3 | 3 | 1 | 1 | -1 |
| OPM % | 0.13% | 7.07% | 5.01% | 2.14% | 1.56% | 7.26% | 7.65% | 6.60% | 12.23% | 10.75% | 4.35% | 3.32% | -5.85% |
| Other Income | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| -1 | 1 | 1 | 0 | -0 | 1 | 1 | 2 | 3 | 2 | 0 | 1 | -2 | |
| Tax % | -0.00% | 0.00% | 5.00% | 0.00% | -0.00% | 0.00% | 0.00% | 11.92% | 0.00% | 0.00% | 0.00% | 0.00% | -0.00% |
| Net Profit | 0 | 0 | 0 | 0 | -24 | -40 | -46 | -15 | 96 | 80 | 55 | 15 | -2 |
| -2 | -1 | -2 | -4 | -1 | -2 | -1 | -1 | 3 | 3 | 2 | 1 | -0 | |
| Equity Capital | 25 | 26 | 26 | 26 | 26 | 26 | 26 | 29 | 29 | 29 | 29 | 29 | 29 |
| Reserves | 49 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Promoter Pledge % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| 77 | 91 | 63 | 79 | 83 | 86 | 83 | |
| 77 | 105 | 90 | 76 | 81 | 79 | 78 | |
| Operating Profit | 1 | -13 | -26 | 4 | 6 | 8 | — |
| OPM % | 2 | -15 | -41 | 5 | 7 | 10 | — |
| Other Income | 1 | 1 | 0 | 1 | 4 | 1 | 1 |
| Interest | 3 | 3 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 7 | 7 | 7 | 2 | 2 | 2 | 2 |
| -9 | -24 | -38 | -20 | -10 | 25 | 1 | |
| Tax % | -115 | 19 | 19 | -0 | -2 | 0 | 0 |
| Net Profit | -19 | -19 | -31 | -20 | -10 | 25 | 1 |
| EPS | -7 | -8 | -13 | -7 | -3 | 8 | — |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Minority Interest | 0 | 8 | 10 | 0 | 0 | 0 | 0 |
| Share of Associates | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Adjusted EPS | -8 | -5 | -8 | -7 | -3 | 8 | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 2%
- 3 Years:
- 11%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- -4%
- 5 Years:
- -12%
- 3 Years:
- -14%
- 1 Year:
- -54%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- -16%
- 3 Years:
- -6%
- Last Year:
- 22%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| LIABILITIES | - | - | - | - | - | - |
| Equity Capital | 25 | 25 | 25 | 26 | 29 | 29 |
| 54 | 63 | 49 | 39 | 69 | 93 | |
| 17 | 15 | 6 | 5 | 6 | 6 | |
| Trade Payables | 31 | 28 | 23 | 15 | 14 | 11 |
| 35 | 64 | 7 | 4 | 6 | 8 | |
| Total Liabilities | 162 | 195 | 110 | 90 | 124 | 148 |
| ASSETS | - | - | - | - | - | - |
| 108 | 110 | 15 | 14 | 14 | 15 | |
| Capital Work in Progress | 1 | 15 | 0 | 0 | 0 | 1 |
| 0 | 0 | 64 | 43 | 74 | 92 | |
| 24 | 28 | 11 | 10 | 9 | 11 | |
| 0 | 0 | 0 | 16 | 20 | 16 | |
| Cash & Bank | 2 | 4 | 1 | 1 | 1 | 8 |
| 29 | 38 | 18 | 7 | 6 | 5 | |
| Total Assets | 162 | 195 | 110 | 90 | 124 | 148 |
| Total Debt | 31 | 24 | 6 | 5 | 6 | 7 |
| Net Working Capital | -16 | 12 | -5 | 8 | 11 | 16 |
| Contingent Liabilities | 7 | 24 | 20 | 71 | 76 | 123 |
| Book Value per Share | 32.04 | 35.42 | 29.94 | 24.99 | 33.30 | 41.64 |
| Face Value | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 4 | -37 | -14 | -10 | 3 | 9 | |
| Cash from Investing | -5 | -25 | 0 | 0 | -45 | -3 |
| Cash from Financing | 1 | 64 | 11 | 10 | 42 | 0 |
| 0 | 2 | -3 | 0 | -0 | 7 | |
| Free Cash Flow | 4 | -61 | -14 | -10 | 1 | 7 |
| OCF / Net Profit | -0.23 | 1.94 | 0.47 | 0.50 | -0.26 | 0.38 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 | 0 | -78 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| PER SHARE | ||||||
| EPS (₹) | -7.84 | -4.57 | -8.46 | -7.46 | -3.38 | 8.35 |
| Book Value (₹) | 32.04 | 35.42 | 29.94 | 24.99 | 33.30 | 41.64 |
| Dividend per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash EPS (₹) | -4.90 | -4.80 | -9.63 | -6.79 | -2.84 | 8.89 |
| PROFITABILITY | ||||||
| Operating Margin % | 1.63% | -14.75% | -41.46% | 3.85% | 1.62% | 8.23% |
| Net Margin % | -25.08% | -21.18% | -49.12% | -24.65% | -12.07% | 28.67% |
| ROE % | -24.48% | -23.18% | -38.46% | -28.08% | -12.18% | 22.27% |
| ROCE % | -5.33% | -18.72% | -37.83% | -24.92% | -10.03% | 21.72% |
| -11.95% | -10.83% | -20.41% | -19.59% | -9.31% | 18.08% | |
| EFFICIENCY | ||||||
| Debtor Days | 65 | 63 | 88 | 67 | 80 | 77 |
| Inventory Days | 112 | 102 | 112 | 48 | 42 | 43 |
| Payable Days | 237 | 171 | 185 | 125 | 98 | 90 |
| -61 | -6 | 15 | -10 | 24 | 30 | |
| FINANCIAL HEALTH | ||||||
| Debt to Equity (x) | 0.40x | 0.28x | 0.08x | 0.08x | 0.06x | 0.06x |
| Interest Coverage (x) | -1.90x | -6.72x | -16.58x | -22.16x | -8.52x | 30.43x |
| 0.74x | 1.25x | 0.84x | 1.35x | 1.48x | 1.72x | |
| GROWTH | ||||||
| Revenue Growth % | 0.00% | 18.04% | -30.69% | 25.76% | 3.86% | 3.85% |
| Operating Profit Growth % | 0.00% | -1170.52% | -94.85% | 115.92% | 39.52% | 41.36% |
| Net Profit Growth % | 0.00% | 0.33% | -60.76% | 36.90% | 49.13% | 346.65% |
| 0.00% | 0.00% | 0.00% | 11.74% | 54.67% | 346.65% | |
| VALUATION | ||||||
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 4.49x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 3.71x | 3.23x | 0.90x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00x | 0.00x | 0.00x | 59.41x | 55.34x | 13.39x |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-03 - Brooks Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 03, 2026
2026-08-22 - Please find enclosed herewith Addendum to the Notice of 24th Annual General Meeting.
2026-08-21 - Addendum to the Notice of 24th Annual General Meeting of the Company.
2026-08-17 - Brooks Laboratories Limited has informed the Exchange regarding 'Intimation Of Record Date, E-Voting Dates And Book Closure Date'.
2026-08-14 - Brooks Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-13 - Brooks Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-13 - Newspaper publication regarding 24th AGM of the Company to be held on 3rd September 2026.
2026-08-12 - Letter to Shareholders - Annual Report for the FY 2025-26.
2026-08-12 - Brooks Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 03, 2026
News
Recent coverage and analyst commentary for BROOKS
Loading news…
AI Stock Analyst
Brooks Laboratories Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account